<DOC>
	<DOC>NCT01451632</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.</brief_summary>
	<brief_title>A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers</brief_title>
	<detailed_description>This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>No standard options remaining Adequate liver and kidney functions 18 years of age or above History of any secondary active cancer in the last 3 years. Pregnant or breast feeding History of severe allergic reactions or contraindications to cetuximab or irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Metastatic Colorectal cancer</keyword>
	<keyword>Kras wild-type</keyword>
	<keyword>Squamous cell head and neck cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>ErbB3</keyword>
	<keyword>MM-121</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Irinotecan</keyword>
</DOC>